Stock Analysis & Ideas

AstraZeneca’s stock is well suited for long-term growth

Story Highlights

The COVID-19 pandemic has brought pharma stocks on the radar of investors – but does Astra Zeneca have what it takes to deliver long-term?

Pharma giant AstraZeneca (GB:AZN) became a globally famous name thanks to its COVID vaccine and is among the biggest companies in the FTSE 100 – not to mention the fact that its stock has generated around 60% returns in the last three years.

Pharma stocks are primarily influenced by the revenue generated by the companies’ drugs. AZN has a strong pipeline of drugs ahead, which could lead to a substantial push in revenues and stock price.

First-half results: Robust growth

The company recently reported its half-yearly results for 2022 with solid revenue numbers. The total revenue for the group increased by 48% to $22.2 billion. The revenues were mainly driven by the biopharmaceuticals segment, which contributed around 47% of the total revenues.

Revenues grew by 31% to $10.4 billion because of solid sales of Farxiga, a type 2 diabetes drug, and other COVID-19 medicines.

The top-line growth led to a solid increase in earnings per share (EPS). The core EPS was reported at $3.61, which was 44% higher than the previous year. The EPS benefited from a core tax rate of 15%. For the second half of 2022, the company expects the tax rate to be in the range of 18–22%.

AZN has increased its full-year 2022 guidance for revenue, considering strong results across the various business segments. Revenue is now expected to grow by a low twenties percentage. Core EPS is expected to rise by a percentage in the mid-to-high twenties.

A diverse and solid pipeline

The company is betting big on its revenue because of a solid pipeline ahead. The company’s pipeline is spread across various stages of clinical trials. It has a total of 184 projects in the pipeline and 17 new molecular entities in late-stage pipeline.

Last month, investors welcomed the news that its asthma drug Tezspire and autoimmune drug Ultomiris had received EU marketing approval. Also, its breast cancer drug Enhertu got a priority review by the U.S. FDA. Enhertu is already approved by the EU for expanded use.

The pipeline shows that the company will continue to be a strong player in the pharma industry for many years to come.

View from the City

According to TipRanks’ analyst rating consensus, AZN stock has a Strong Buy rating from 13 analysts. It includes 10 Buy and three Hold recommendations.

It has an average price target of 11,184.17p, which represents a 3.04% change in the price from the level of 10,766p. The price has a low and high forecast of 15,300p and 1,010p, respectively.


The AZN stock is a gem for investors who prefer stability over fast and high growth.

The company’s guidance numbers and drug pipeline are enough to drive long-term growth in revenues, which will be reflected in the share prices as well.


Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More